Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
GRI Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GRI
Nasdaq
8731
https://www.gribio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for GRI Bio Inc
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
- Apr 25th, 2024 1:15 pm
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
- Apr 16th, 2024 12:35 pm
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
- Apr 8th, 2024 12:35 pm
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
- Apr 1st, 2024 11:35 am
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
- Mar 28th, 2024 1:00 pm
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
- Mar 14th, 2024 12:45 pm
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
- Mar 4th, 2024 1:30 pm
GRI Bio Announces Pricing of $5.5 Million Public Offering
- Feb 2nd, 2024 1:00 pm
GRI Bio Announces Reverse Stock Split
- Jan 26th, 2024 1:05 pm
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment
- Dec 6th, 2023 6:47 pm
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
- Dec 5th, 2023 2:05 pm
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
- Nov 27th, 2023 1:35 pm
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 15th, 2023 1:05 pm
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
- Oct 31st, 2023 12:45 pm
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
- Oct 19th, 2023 12:45 pm
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
- Oct 17th, 2023 12:35 pm
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
- Oct 11th, 2023 1:05 pm
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
- Oct 5th, 2023 12:45 pm
September Is Pulmonary Fibrosis Awareness Month: Here’s What One Company Is Doing To Develop A Treatment For This Deadly Disease
- Sep 29th, 2023 1:00 pm
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 1:05 pm
Scroll